Compounded tirzepatide has not undergone FDA review for safety, efficacy, or manufacturing consistency. While some compounding pharmacies operate at high standards, compounded medications are not required to demonstrate bioequivalence to FDA-approved drugs, undergo clinical trials, or meet the same manufacturing oversight. At PEAK, we prescribe only FDA-approved tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) to ensure the highest standard of patient safety.
FDA-approved vs. compounded tirzepatide
This table summarizes the regulatory and clinical differences.
| FDA-Approved (Zepbound/Mounjaro) | Compounded Tirzepatide | |
|---|---|---|
| Regulation | FDA-reviewed Phase III trials; cGMP manufacturing | State pharmacy board oversight; no FDA review |
| Clinical trials | Tested in thousands of patients over years | No independent efficacy or safety trials required |
| Dosing accuracy | Pre-filled pens with verified, consistent doses | Vials requiring manual measurement; dosing variability |
| Purity & potency | Every batch tested to federal standards | Testing standards vary by pharmacy; FDA has issued warnings |
| Insurance coverage | Often covered with prior authorization | Rarely covered; typically cash-pay only |
| Cost (typical) | high out-of-pocket pricing | moderate monthly self-pay pricing |
| Post-market surveillance | FDA MedWatch adverse event tracking | Limited tracking; pharmacies report voluntarily |
| Long-term safety data | Years of documented outcomes in clinical use | No systematic long-term safety data |
Note: This reflects regulatory categories, not individual pharmacy quality. Some compounding pharmacies exceed minimum standards, but the regulatory floor is meaningfully different.
What compounding actually is
Pharmaceutical compounding serves an important medical purpose. Compounding pharmacies create customized formulations for patients with specific needs—for example, a child who needs a liquid version of a medication that only comes in tablet form, or a patient with a documented allergy to an inactive ingredient in a commercial product.
Compounding is regulated at the state level by pharmacy boards, not by the FDA. Compounders are not required to conduct clinical trials, demonstrate bioequivalence to FDA-approved products, or follow the same manufacturing standards (current Good Manufacturing Practices, or cGMP) that apply to pharmaceutical manufacturers.
Most compounded tirzepatide is not being created to address a clinical need for customization. It is being compounded because it is cheaper than FDA-approved Zepbound or Mounjaro, and because supply shortages (which have eased significantly) created market demand for alternatives. For a parallel analysis of compounded semaglutide, see our guide on why PEAK does not prescribe compounded semaglutide.
The question is not whether compounding pharmacies can create tirzepatide. The question is whether that product carries the same level of evidence, oversight, and assurance as the FDA-approved version.
FDA warnings and safety concerns
The FDA has issued multiple safety alerts and warning letters regarding compounded semaglutide and tirzepatide products. Key concerns include:
Dosing errors and adverse events
The FDA has received reports of adverse events—including hospitalizations—linked to dosing errors with compounded GLP-1 products. In some cases, patients received incorrect doses due to pharmacy compounding errors. In others, patients misunderstood how to measure and administer doses from multi-use vials.
Use of unapproved salt forms
Many compounded versions use tirzepatide acetate or tirzepatide sodium rather than the base form used in FDA-approved products. These salt forms have not been independently evaluated in clinical trials. Their absorption, efficacy, and safety profile have not been verified to match the FDA-approved formulation.
Sterility and contamination concerns
Injectable medications must be sterile. Compounding pharmacies are required to follow USP <797> sterile compounding standards, but oversight is variable. The FDA has issued warnings to compounding pharmacies for sterility failures that could lead to serious infections.
Lack of stability data
FDA-approved medications include extensive stability testing to ensure the drug remains potent and safe throughout its shelf life. Compounded products typically do not include equivalent stability data, which means there is less certainty about degradation over time—especially if products are shipped or stored improperly.
In December 2024, the FDA announced that tirzepatide shortages had resolved and that compounding of tirzepatide would no longer be permitted under the shortage exemption that previously existed. Many compounding pharmacies continue to compound tirzepatide under different legal interpretations, but this regulatory uncertainty adds risk for patients.
Why patients consider compounded tirzepatide
We do not judge patients who have used or considered compounded medications. The reasons are understandable:
Cost. FDA-approved tirzepatide is expensive without insurance—often high out-of-pocket pricing per month. Compounded versions can cost moderate monthly self-pay pricing. For patients without insurance coverage, this price difference is significant.
Access during shortages. When Zepbound and Mounjaro were in short supply, compounded versions were often available when FDA-approved products were not. Many patients turned to compounding out of necessity.
Convenience. Some telehealth companies aggressively market compounded tirzepatide as equivalent to FDA-approved versions but faster and cheaper. For patients working through insurance prior authorizations, the streamlined process is appealing.
At PEAK, we recognize these barriers are real. That is one reason we accept most major insurance plans, handle prior authorization on your behalf, and work with patients to explore manufacturer savings programs and coverage pathways. Patients often ask whether a generic version of these medications will become available—the short answer is not yet, but we keep patients informed about developments. We believe access to safe, evidence-based treatment should not depend on a patient's ability to pay cash—but we also believe the solution is better insurance navigation, not unregulated alternatives.
PEAK's clinical position
Our position is straightforward: we prescribe FDA-approved tirzepatide exclusively. This is not a competitive stance or a marketing decision—it is a clinical and ethical one.
When you receive a prescription at PEAK, you can be confident that:
• The medication has been tested in large-scale clinical trials involving thousands of patients.
• Every batch meets federal manufacturing and purity standards.
• The dose you receive is verified and consistent.
• Adverse events are tracked through FDA post-market surveillance systems.
• Your insurance company recognizes the medication as a covered, evidence-based treatment (subject to prior authorization).
We understand that cost is a barrier. We work with every patient to verify insurance coverage, submit prior authorizations, and explore manufacturer savings programs before prescribing. If your insurance denies coverage, we discuss alternatives—switching to a covered GLP-1, appealing the denial, or adjusting your treatment plan. What we do not do is prescribe compounded alternatives as a workaround.
If you are currently using compounded tirzepatide and want to transition to FDA-approved Zepbound, we can help you through that process, map your current dose to the FDA-approved equivalent, and handle the insurance authorization. To understand what kind of results patients are achieving with the FDA-approved version, read our overview of Zepbound weight loss results.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
